Inventor · disambiguated record
Lutz Jermutus
Also filed as: JERMUTUS LUTZ · JERMUTUS LUTZ U · JERMUTUS LUTZ ULRICH · JERMUTUS LUTZ ULRICH JOCHEN
23 granted patents·13 pending applications·330 citations·filing 2001–2022
96Inventor score
Top patents by PatentIndex Score
36 records- 0197US8383780B2Antibodies to TGFβGENZYME CORP·Filed 2010·Granted Feb 26, 2013·66 cites·6 claims
- 0297US7723486B2Antibodies to TGF-βOPTEIN INC·Filed 2006·Granted May 25, 2010·71 cites·14 claims
- 0395US8591901B2Antibodies to TGF-βLEDBETTER STEVEN R·Filed 2012·Granted Nov 26, 2013·50 cites·25 claims
- 0494US9938356B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2015·Granted Apr 10, 2018·26 cites·9 claims
- 0594US9481726B2Antibodies to TGF-βGENZYME CORP·Filed 2015·Granted Nov 1, 2016·7 cites·12 claims
- 0694US9090685B2Antibodies to TGF-betaGENZYME CORP·Filed 2013·Granted Jul 28, 2015·12 cites·16 claims
- 0791US10287362B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2018·Granted May 14, 2019·10 cites·15 claims
- 0890US6589741B2Polysome display in the absence of functional ssrA-RNAUNIV ZUERICH·Filed 2001·Granted Jul 8, 2003·33 cites·9 claims
- 0988US7947273B2Human antibody molecules for IL-13MEDIMMUNE LTD·Filed 2007·Granted May 24, 2011·10 cites·18 claims
- 1084US7935343B2Human antibody molecules for IL-13MEDIMMUNE LTD·Filed 2004·Granted May 3, 2011·14 cites·45 claims
- 1183US2023078449A1Antibodies to TGF-BetaGENZYME CORP·Filed 2022·Application pending·0 cites
- 1281US11065336B2Conjugates for targeting and clearing aggregatesMEDIMMUNE LTD·Filed 2019·Granted Jul 20, 2021·4 cites·12 claims
- 1381US10556968B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2019·Granted Feb 11, 2020·2 cites·8 claims
- 1481US9856317B2Human antibody molecules for IL-13MEDIMMUNE LTD·Filed 2016·Granted Jan 2, 2018·2 cites·19 claims
- 1580US7829090B2Human antibody molecules for IL-13MEDIMMUNE LTD·Filed 2004·Granted Nov 9, 2010·9 cites·22 claims
- 1679US8088736B2CTLA-4 protein variantsFRANKS RUTH·Filed 2007·Granted Jan 3, 2012·9 cites·19 claims
- 1779US2023340152A1Binding molecules specific for cd73 and uses thereofMEDIMMUNE LTD·Filed 2022·Application pending·0 cites
- 1875US10184008B2Blood brain barrier transport molecules and uses thereofMEDIMMUNE LTD·Filed 2015·Granted Jan 22, 2019·3 cites·27 claims
- 1975US2021061897A1Antibodies to TGF-BetaGENZYME CORP·Filed 2020·Application pending·0 cites
- 2073US10781252B2Antibodies to TGF-βGENZYME CORP·Filed 2018·Granted Sep 22, 2020·0 cites·11 claims
- 2172US11525012B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2019·Granted Dec 13, 2022·0 cites·6 claims
- 2272US2007134246A1Antibodies to TGF-BETACAMBRIDGE ANTIBODY TECH·Filed 2007·Application pending·0 cites
- 2372US2007264255A1Antibodies to TGF-betaCAMBRIDGE ANTIBODY TECH·Filed 2007·Application pending·0 cites
- 2471US9315575B2Methods of treatment using human antibody molecules for IL-13MONK PHILLIP DAVID·Filed 2010·Granted Apr 19, 2016·2 cites·72 claims
- 2567US10174108B2Antibodies to TGF-betaGENZYME CORP·Filed 2016·Granted Jan 8, 2019·0 cites·18 claims
- 2666US12076406B2Conjugates for targeting and clearing aggregatesMEDIMMUNE LTD·Filed 2021·Granted Sep 3, 2024·0 cites·24 claims
- 2762US2018230209A1Human antibody molecules for il-13MEDIMMUNE LTD·Filed 2017·Application pending·0 cites
- 2860US2022041681A1Glucagon and glp-1 co-agonists for the treatment of obesityMEDIMMUNE LTD·Filed 2021·Application pending·0 cites
- 2958US10676517B2Glucagon and GLP-1 co-agonists for the treatment of obesityMEDIMMUNE LTD·Filed 2017·Granted Jun 9, 2020·0 cites·15 claims
- 3053US2020354426A1Glucagon and glp-1 co-agonists for the treatment of obesityMEDIMMUNE LTD·Filed 2020·Application pending·0 cites
- 3150US2021213104A1Glucagon and glp-1 co-agonists for the treatment of chronic kidney disease and diabetic kidney disease in type 2 diabetesMEDIMMUNE LTD·Filed 2021·Application pending·0 cites
- 3248US2010184959A1Polypeptide VariantsMEDIMMUNE LTD·Filed 2008·Application pending·0 cites
- 3342US8288123B2Methods and means relating to protein variantsBUCHANAN ANDREW·Filed 2006·Granted Oct 16, 2012·0 cites·41 claims
- 3441US2022249617A1Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptidesMEDIMMUNE LTD·Filed 2020·Application pending·0 cites
- 3539US2008194475A1Erythropoietin Protein VariantsBUCHANAN ANDREW·Filed 2005·Application pending·0 cites
- 3632US2012237496A1Protease variantsBIRKENFELD JOERG·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →